Clinical Trials Update

​
Brensocatib

Insmed has completed the enrollment of over 1700 adult patients in the ASPEN study of brensocatib to treat bronchiectasis.

This is the largest bronchiectasis study to date. Patients have been enrolled and randomized to receive brensocatib 10 mg, brensocatib 25 mg, or placebo once daily for 52 weeks, followed by 4 weeks off treatment. The primary endpoint is the rate of pulmonary exacerbations over the 52-week treatment period.

Insmed anticipates reporting results from adults in the ASPEN trial in the second quarter of 2024. For more information on the study, go to:

https://classic.clinicaltrials.gov/ct2/show/NCT04594369?term=brensocatib&cond=Bronchiectasis&draw=2&rank=1


ARINA-1

The Renovion trial for ARINA-1 in non-cystic fibrosis bronchiectasis (NCFBE) has completed enrollment in December 2023 and will have data available in the first half of 2024.  I will provide you with a summary of the results as soon as they are available.  Thank you to everyone who participated or expressed an interest in the trial.  These trials help us take big steps towards more treatments for everyone!

For more information on the study, click this link: https://classic.clinicaltrials.gov/ct2/results?cond=Bronchiectasis&term=ARINA-1&cntry=&state=&city=&dist=

MAC 2v3

Are you considering antibiotics for a MAC infection? If so, I want to share with you that for the past 2 years I have been on the patient advisory committee for the MAC2v3 study.  

The study is designed to test whether only two drugs (azithromycin and ethambutol) can be as effective in treating MAC as the current “big three” (azithromycin, ethambutol, and rifampin) treatment.  

The trial is for 12 months. To participate, you need to be able to produce a sputum sample.  

They currently have an amazing network of 30+ physicians (including mine!) at 22 sites from  Hawaii to New York to Texas to Toronto.  

And, great news!!!  

Patients can stay with their doctor and be referred virtually for this study without the need to travel to test sites. 

If you would like more information, they have a website mac2v3study.org and I have found them to be excellent to work with. Currently, there are about 400 enrollees and they need another 100  to complete the study. Take a look at their website and email them with your questions.  

#brensocatib #Insmed #ARINA-1 #Renovion #MAC2v3 #bronchiectasis #ntmlungdisease #MAClungdisease